Benitec Biopharma (BNTC) Company Report

Benitec Biopharma Inc. reported a net loss of $9.0 million, or $(0.22) per basic and diluted share, for the first fiscal quarter ended September 30, 2025, with total expenses reaching $9.8 million.
The company's lead candidate, BB-301, received Fast Track Designation from the FDA after positive interim Phase 1b/2a clinical study results demonstrated a 100% responder rate in Cohort 1.
Benitec successfully raised approximately $100 million through a public offering of common stock, which is expected to fund the advancement of the BB-301 registrational program.
As of September 30, 2025, the company held $94.5 million in cash and cash equivalents.

Nov 14, 2025, 10:31 PM

Benitec Biopharma Inc. Announces Pricing of Common Stock Offerings

BNTC

Benitec Biopharma Inc. announced the pricing of an underwritten public offering of 5,930,000 shares and a concurrent registered direct offering of 1,481,481 shares of common stock at $13.50 per share on November 5, 2025.
The aggregate gross proceeds from both offerings are expected to be approximately $100 million.
The company granted the underwriters a 30-day option to purchase up to an additional 889,500 shares of common stock.
The net proceeds from this financing, combined with existing cash, will be used to support product candidate programs, working capital, and other general corporate purposes.
The offerings are expected to close on November 7, 2025.

Nov 7, 2025, 2:29 AM

Benitec Biopharma Reports Full Year 2025 Financial Results and BB-301 Clinical Progress

BNTC

Earnings

New Projects/Investments

Benitec Biopharma Inc. reported a net loss attributable to common shareholders of $37.9 million, or $1.05 per basic and diluted share, for the full year ended June 30, 2025. This compares to a net loss of $22.4 million, or $1.22 per basic and diluted share, for the prior year.
Total expenses for the year ended June 30, 2025, increased to $41.8 million from $22.5 million in the previous year, primarily due to higher general and administrative expenses of $23.4 million (including $14.5 million in share-based compensation) and research and development expenses of $18.3 million.
As of June 30, 2025, the company held $97.7 million in cash and cash equivalents.
The company anticipates providing interim clinical study results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study and expects to begin enrollment of subjects into Cohort 2 in the fourth calendar quarter of 2025.